This systematic review and meta-analysis of VLNC RCTs found minimal evidence of compensation among people assigned to smoke VLNCs.
Searching for Solutions
LA Times headlines have been tracking the broader rollout of contingency management, and there is genuine reason for optimism.
STAT’s investigation turned up numerous ways the nation can curb excessive drinking and its related harms.
Alcohol-related mortality has increased substantially over 55 years, with profound demographic shifts including a complete racial disparity inversion and narrowing gender gap.
No summary available
No summary available
No summary available
This publication provides an overview of the Certified Community Behavioral Health Clinic (CCBHC) model, including its purpose, core service requirements, and impact on expanding access to comprehensive mental health and substance use disorder care.
These findings suggest that naloxone access still depends on location and pharmacy type, highlighting the urgent need to make this medication affordable and available to everyone, everywhere.
No summary available
Catch up on missed sessions or revisit past presentations. All Journal Club recordings are available in the Course Materials section. Once registered, you can access the recordings, presentations, and article links on the Journal Club page.
Stimulant medications dexamphetamine and methylphenidate appear comparable in short-term symptom response and 12-month persistence after initial randomised allocation, but dexamphetamine may be associated with greater weight loss.
No summary available
No summary available
The Congressional Psychedelics Advancing Therapies Caucus released a report today outlining recommendations for integrating psychedelic-assisted therapy — a combination of psychiatric counseling with controlled doses of psychedelic drugs such as psilocybin or MDMA, also known as ecstasy or molly, to treat mental illnesses — into the nation’s health care system.
No summary available
No summary available
The FDA cleared Motivista, a prescription digital therapeutic, to treat negative symptoms of schizophrenia in adults in conjunction with clinician-managed outpatient care. The authorization was supported by results from the Phase 3 CONVOKE trial, in which patients using Motivista showed significantly greater improvement in negative symptoms than those using a control app, with strong user engagement and no serious treatment-related adverse events reported.
Targeted interventions to address withdrawal, side effects, dependence fears, and housing barriers may boost uptake of ED buprenorphine, a study of adults with opioid use disorder suggested.
The guidelines address the sharp rise in obesity among children and adolescents, setting out how health systems and health workers can deliver timely, evidence-based and people-centered care.
Genome-wide association studies and polygenic risk scores have identified multiple gene loci and variants contributing to the susceptibility to TUD.
Specific gambling behaviors increase risk of problem gambling for SUD patients. SUD treatment programs should screen for and address problem gambling.
Researchers examined cohorts over time to evaluate trends in withdrawal management after the emergence of medetomidine in the unregulated drug supply.
The opioid lawsuits are expected to provide over $50 billion over two decades.
Creating partnerships with community organizations, leadership from an ED champion, and pairing implementation with education for ED staff are key for programmatic success.